Literature DB >> 15505990

There are no acute cardiac effects of a single iv dose of human ghrelin in severe growth hormone deficient patients.

J A M J L Janssen1, D Poldermans, L J Hofland, E C Vourvouri, A F Muller, J J Bax, R Deghenghi, F Broglio, E Ghigo, A J van der Lely.   

Abstract

It has previously been suggested that ghrelin mediates GH-independent biologic activities on the heart. We investigated the acute effects on cardiac contraction of a single iv administration of human ghrelin (in a dose of 1 microg/kg) in severe untreated GH deficient subjects. Prior to the ghrelin infusion, an echocardiographic examination was performed at rest (baseline), after physiologic saline and during dobutamine stress echocardiography (DSE) to exclude a preexisting (subclinical) myocardial dysfunction. To evaluate the acute cardiac effect of infusion and during DSE the velocity of left ventricular (LV) wall contraction was measured continuously by echocardiography. Despite severe GH deficiency we observed in all subjects a normal cardiac function at rest after physiologic saline and during DSE. No acute changes in cardiac performance or cardiac parameters could be observed after a single iv dose of ghrelin. Also, no important increase in GH secretion was detected after ghrelin administration. Our study suggests that, in contrast to hexarelin, a single iv administration of ghrelin in a physiological dose has no acute effects on cardiac function in severe GH deficiency. This suggests that GH-independent effects of ghrelin play no important role in the acute regulation of cardiac function in man.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15505990     DOI: 10.1007/BF03347499

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  19 in total

1.  The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors.

Authors:  M Korbonits; S A Bustin; M Kojima; S Jordan; E F Adams; D G Lowe; K Kangawa; A B Grossman
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

2.  Regional wall motion index for infarct and noninfarct regions after reperfusion in acute myocardial infarction: comparison with global wall motion index.

Authors:  P D Bourdillon; T M Broderick; S G Sawada; W F Armstrong; T Ryan; J C Dillon; N S Fineberg; H Feigenbaum
Journal:  J Am Soc Echocardiogr       Date:  1989 Nov-Dec       Impact factor: 5.251

3.  Hemodynamic and hormonal effects of human ghrelin in healthy volunteers.

Authors:  N Nagaya; M Kojima; M Uematsu; M Yamagishi; H Hosoda; H Oya; Y Hayashi; K Kangawa
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2001-05       Impact factor: 3.619

4.  Dobutamine stress echocardiography: correlation with coronary lesion severity as determined by quantitative angiography.

Authors:  D S Segar; S E Brown; S G Sawada; T Ryan; H Feigenbaum
Journal:  J Am Coll Cardiol       Date:  1992-05       Impact factor: 24.094

5.  Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans.

Authors:  G Bisi; V Podio; M R Valetto; F Broglio; G Bertuccio; G Del Rio; E Arvat; M F Boghen; R Deghenghi; G Muccioli; H Ong; E Ghigo
Journal:  J Endocrinol Invest       Date:  1999-04       Impact factor: 4.256

6.  Cardiac effects of hexarelin in hypopituitary adults.

Authors:  G Bisi; V Podio; M R Valetto; F Broglio; G Bertuccio; G Aimaretti; E Pelosi; G Del Rio; G Muccioli; H Ong; M F Boghen; R Deghenghi; E Ghigo
Journal:  Eur J Pharmacol       Date:  1999-09-17       Impact factor: 4.432

7.  Growth hormone secretagogue binding sites in peripheral human tissues.

Authors:  M Papotti; C Ghè; P Cassoni; F Catapano; R Deghenghi; E Ghigo; G Muccioli
Journal:  J Clin Endocrinol Metab       Date:  2000-10       Impact factor: 5.958

8.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

9.  Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats.

Authors:  G Rossoni; V De Gennaro Colonna; M Bernareggi; G L Polvani; E E Müller; F Berti
Journal:  J Cardiovasc Pharmacol       Date:  1998-08       Impact factor: 3.105

10.  Ghrelin plays a minor role in the physiological control of cardiac function in the rat.

Authors:  Antonio Torsello; Elena Bresciani; Giuseppe Rossoni; Roberta Avallone; Giovanni Tulipano; Daniela Cocchi; Ilaria Bulgarelli; Romano Deghenghi; Ferruccio Berti; Vittorio Locatelli
Journal:  Endocrinology       Date:  2003-05       Impact factor: 4.736

View more
  1 in total

Review 1.  Clinical review: The human experience with ghrelin administration.

Authors:  Margaret C Garin; Carrie M Burns; Shailja Kaul; Anne R Cappola
Journal:  J Clin Endocrinol Metab       Date:  2013-03-26       Impact factor: 5.958

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.